← All trials
NCT05341947
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Jun 30, 2025
- First posted
- Apr 22, 2022
- Last posted
- Apr 22, 2022
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cedars-Sinai Medical CenterLead sponsor
- Cedars-Sinai Medical CenterOverall official - principal investigator
- Cedars-Sinai Medical CenterSponsor investigator
- Cedars-Sinai Medical CenterOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.